Maze Therapeutics share price logo

Maze Therapeutics Share Price

NASDAQ: MAZE

Small Cap

$32.40

-0.84

(-2.53%)

as on

Maze Therapeutics Stock Performance

as on November 5, 2025 at 2:29 am IST

  • Day's Low

    Day's High

    $31.47
    $33.34
    downward going graph

    2.87%

    Downside

    2.90%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $6.71
    $34.29
    downward going graph

    79.29%

    Downside

    5.83%

    Upside

    downward going graph

Maze Therapeutics share price movements today

Previous Close
$33.24
Open
$32.73
Volume
354.1K
Day's Low - High
$31.47 - $33.34
52 Week Low - High
$6.71 - $34.29

Maze Therapeutics Historical Returns

1 Month Return
+ 22.61 %
3 Month Return
+ 117.97 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Maze Therapeutics Stock Fundamentals & Key Indicators

Check Maze Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$525.3M

EPS (TTM)

0

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Maze Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Maze Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Maze Therapeutics image
Maze Therapeutics
NA$525.3MNANA32.97%
Insmed Incorporated image
Insmed Incorporated
BUY$39.7B455.58%-16.34-264.83%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$60.2B211.18%1425.121.36%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$109.1B98.06%30.3131.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$68.5B9.39%15.6232.13%

Maze Therapeutics Stock’s Investor Sentiment and Interest

Search interest for Maze Therapeutics Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-50% versus previous 30 day period

Maze Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
165
2
-
-
-
Gross Profit
-1
0
0
165
2
0
0
0
Operating Income
-25
-23
-28
139
-24
-29
-35
-36
EBITDA
-24
-22
-27
140
-23
-29
-35
-36
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
1
0
0
0
0
0
0
0
Income Before Tax
-24
-26
-32
140
-25
-29
-32
-33
Income Tax Expense
-
-
-
1
0
0
-
-
Net Income
-24
-26
-32
139
-24
-29
-32
-33
Net Profit Margin
0.00%
0.00%
0.00%
84.28%
-990.08%
0.00%
0.00%
0.00%

Maze Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
167
Gross Profit
-3
-4
167
Operating Income
-111
-98
57
EBITDA
-107
-94
60
Interest Expense
-
-
-
Depreciation
3
4
3
Income Before Tax
-114
-100
53
Income Tax Expense
-
-
1
Net Income
-114
-100
52
Net Profit Margin
0.00%
0.00%
31.18%

Maze Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-26
-32
139
-24
-29
-32
-33
Operating Cash Flow
-20
-23
145
-23
-22
-29
-30
Investing Cash Flow
0
0
0
0
0
0
0
Financing Cash Flow
16
24
0
-2
70
127
0
Change in Cash
-4
0
145
-25
47
97
-29

Maze Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Net Income
-100
52
Operating Cash Flow
-86
75
Investing Cash Flow
0
-1
Financing Cash Flow
16
92
Change in Cash
-70
167

Insights on Maze Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MAZE stock has moved up by 22.6%

About Maze Therapeutics

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
OrganisationMaze Therapeutics
Headquarters171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
CEODr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
E-voting on sharesClick here to vote

Key Management of Maze Therapeutics

Name

Title

Dr. Harold S. Bernstein M.D., Ph.D.

President of Research & Development and Chief Medical Officer

Mr. Matt Krause

Senior Vice President of Human Resources

Ms. Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Ms. Amy Bachrodt

Senior Vice President of Finance

Mr. Maarten Hoek

Senior Vice President of Research

Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.

CEO & Director

Ms. Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Mr. Misbah Tahir CPA

Chief Financial Officer

Mr. Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Mr. Atul Dandekar

Chief Strategy & Business Officer

FAQs

What is Maze Therapeutics share price today?

Maze Therapeutics share price today is $32.4 as on at the close of the market. Maze Therapeutics share today touched a day high of $33.34 and a low of $31.47.

What is the 52 week high and 52 week low for Maze Therapeutics share?

Maze Therapeutics share touched a 52 week high of $34.29 on and a 52 week low of $6.71 on . Maze Therapeutics stock price today i.e. is closed at $32.4,which is 5.51% down from its 52 week high and 382.86% up from its 52 week low.

What is Maze Therapeutics's market capitalisation today?

Maze Therapeutics market capitalisation is $0.00T as on .

How to invest in Maze Therapeutics Stock (MAZE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Maze Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Maze Therapeutics Shares that will get you 0.0463 shares as per Maze Therapeutics share price of $32.4 per share as on November 5, 2025 at 2:29 am IST.

What is the minimum amount required to buy Maze Therapeutics Stock (MAZE) from India?

Indian investors can start investing in Maze Therapeutics (MAZE) shares with as little as ₹88.67 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.70 in Maze Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Maze Therapeutics share’s latest price of $32.4 as on November 5, 2025 at 2:29 am IST, you will get 0.3086 shares of Maze Therapeutics. Learn more about fractional shares .